Trastuzumab Deruxtecan
This antibody-drug conjugate combines trastuzumab with a chemotherapy payload and is used to treat HER2-positive and certain HER2-low breast cancers and other HER2-expressing cancers. It delivers the chemotherapy directly to cancer cells by using the antibody to seek out HER2-expressing cells, then releasing the toxic drug inside them. A serious lung complication called interstitial lung disease can occur and requires prompt medical attention.
Áreas Terapêuticas
Mecanismo de Ação
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
This antibody-drug conjugate combines trastuzumab with a chemotherapy payload and is used to treat HER2-positive and certain HER2-low breast cancers and other HER2-expressing cancers. It delivers the chemotherapy directly to cancer cells by using the antibody to seek out HER2-expressing cells, then releasing the toxic drug inside them. A serious lung complication called interstitial lung disease can occur and requires prompt medical attention.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Trastuzumab Deruxtecan is an approved drug. It has reached clinical phase 4. It is classified as a Antibody drug conjugate.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297844. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="trastuzumab-deruxtecan"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/trastuzumab-deruxtecan/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/trastuzumab-deruxtecan/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/trastuzumab-deruxtecan/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="trastuzumab-deruxtecan"></drugfyi-drug>